These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer. Osude C; Lin L; Patel M; Eckburg A; Berei J; Kuckovic A; Dube N; Rastogi A; Gautam S; Smith TJ; Sreenivassappa SB; Puri N Cells; 2022 May; 11(10):. PubMed ID: 35626731 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063 [TBL] [Abstract][Full Text] [Related]
7. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374 [TBL] [Abstract][Full Text] [Related]
12. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer. Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010 [TBL] [Abstract][Full Text] [Related]
13. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib. Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC. Kim DM; Kim MJ; Moon JH; Lee EY; Hong JK; Lee S; Koh DI; Ryu YS; Kim SM; Jung SA; Shin JS; Kim J; Park YS; Hong SW; Lee SH; Jung J; Park SS; Kim DY; Kim EH; Jeong HR; Gong JH; Kim J; Chan Kim S; Yu HN; Ki SY; Kim TW; Jin DH Biochem Biophys Res Commun; 2020 Jun; 527(1):305-310. PubMed ID: 32446385 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. Ready N Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534 [TBL] [Abstract][Full Text] [Related]
16. Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies. Kiriwan D; Seetaha S; Jiwacharoenchai N; Tabtimmai L; Sousa SF; Songtawee N; Choowongkomon K Chem Biol Drug Des; 2022 Mar; 99(3):456-469. PubMed ID: 34923743 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Yang Z; Zhang SL; Hu X; Tam KY Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498 [TBL] [Abstract][Full Text] [Related]
18. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. Han W; Pan H; Chen Y; Sun J; Wang Y; Li J; Ge W; Feng L; Lin X; Wang X; Wang X; Jin H PLoS One; 2011; 6(6):e18691. PubMed ID: 21655094 [TBL] [Abstract][Full Text] [Related]
19. Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib. Bielec B; Schueffl H; Terenzi A; Berger W; Heffeter P; Keppler BK; Kowol CR Bioorg Chem; 2020 Jun; 99():103778. PubMed ID: 32229347 [TBL] [Abstract][Full Text] [Related]
20. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Amato KR; Wang S; Tan L; Hastings AK; Song W; Lovly CM; Meador CB; Ye F; Lu P; Balko JM; Colvin DC; Cates JM; Pao W; Gray NS; Chen J Cancer Res; 2016 Jan; 76(2):305-18. PubMed ID: 26744526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]